Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

ACTIV-3/TICO (tixa)
  NCT04501978		 RCTcilgavimab and tixagevimab (Evusheld)placeboCOVID 19 hospitalizedsome concern
710/707 suggested
  • suggested 30 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
  • inconclusive 8 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
ITAC
  NCT04546581		 RCTneutralizing antibodyplaceboCOVID 19 hospitalizedsome concern
301/292 inconclusive
  • inconclusive 6 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
trial did not meet its endpoints (press release)
ACTIV-3 (BRII-196 and BRII-198)
  NCT04501978		 RCTamubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences)placeboCOVID 19 hospitalizedlow
179/183 inconclusive
  • inconclusive 8 % increase in recovery (PE) with a high degree of certainty due to low risk of bias
ACTIV-3/ TICO (sotrovimab)
  NCT04501978		 RCTsotrovimab (Xevudy; VIR-7831)placeboCOVID 19 hospitalizedlow
184/183 inconclusive
  • inconclusive 12 % increase in recovery (PE) with a high degree of certainty due to low risk of bias
Prematurely discontinued for futility after enrollment of 300 patients.
ACTIV-3/TICO LY-CoV555
  NCT04501978		 RCTneutralizing antibodyplaceboCOVID 19 hospitalizedlow
163/151 inconclusive
  • inconclusive 6 % increase in recovery (PE) with a high degree of certainty due to low risk of bias

COVID-19 severe or critically meta-analysis

Lopardo
  NCT04494984		 RCTequine polyclonal antibodies INM005placeboCOVID-19 severe or criticallysome concern
118/123 inconclusive
  • inconclusive 61 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons